Clinical Trial

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

Study acronym: ABBICAR
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study has as goal to evaluate the use of abemaciclib and bicalutamide in androgen receptor positive metastatic triple negative breast cancer.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-04-10; most recent amendment 2026-03-26.
Trial Details
NCT Number NCT06365788
Lead Sponsor Universitaire Ziekenhuizen KU Leuven
Collaborators: Kom Op Tegen Kanker, Eli Lilly and Company, Teva Pharma
Conditions Triple Negative Breast Neoplasms
Enrollment 53 participants
Start Date 2024-04-08
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-01